VEGF-targeted therapy: mechanisms of anti-tumour activity. (Q34791610)

4 August 2017

1 reference

title

VEGF-targeted therapy: mechanisms of anti-tumour activity. (English)

1 reference

4 August 2017

Lee M Ellis

1

1 reference

4 August 2017

Daniel J Hicklin

series ordinal

2

1 reference

4 August 2017

language of work or name

English

0 references

publication date

3 July 2008

1 reference

4 August 2017

Nature Reviews Cancer

1 reference

4 August 2017

8

1 reference

4 August 2017

8

1 reference

4 August 2017

579-591

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc2403

4 August 2017

0 references

cites work

Vascular permeability factor, an endothelial cell mitogen related to PDGF

1 reference

Vascular endothelial growth factor is a secreted angiogenic mitogen

31 March 2020

1 reference

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

31 March 2020

1 reference

Sorafenib in advanced clear-cell renal-cell carcinoma

31 March 2020

1 reference

Detection of circulating endothelial cells: CD146-based magnetic separation enrichment or flow cytometric assay?

31 March 2020

1 reference

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

31 March 2020

1 reference

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

31 March 2020

1 reference

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

31 March 2020

1 reference

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

31 March 2020

1 reference

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

31 March 2020

1 reference

Vascular endothelial growth factor signaling pathways: therapeutic perspective

31 March 2020

1 reference

Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice

31 March 2020

1 reference

Vascular Endothelial Growth Factor Receptor 3 Is Involved in Tumor Angiogenesis and Growth

31 March 2020

1 reference

Molecular mechanisms of lymphangiogenesis in health and disease

31 March 2020

1 reference

Targeting endothelial and tumor cells with semaphorins

31 March 2020

1 reference

Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer

31 March 2020

1 reference

The role of neuropilin in vascular and tumor biology.

31 March 2020

1 reference

VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding

31 March 2020

1 reference

Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor

31 March 2020

1 reference

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

31 March 2020

1 reference

Tumor Angiogenesis: Iris Neovascularization at a Distance From Experimental Intraocular Tumors2

31 March 2020

1 reference

Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?

31 March 2020

1 reference

VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche

31 March 2020

1 reference

Non-uniform plasma leakage affects local hematocrit and blood flow: implications for inflammation and tumor perfusion

31 March 2020

1 reference

Improving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy

31 March 2020

1 reference

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

31 March 2020

1 reference

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma

31 March 2020

1 reference

Sorafenib for the treatment of advanced renal cell carcinoma

31 March 2020

1 reference

A quantitative analysis of kinase inhibitor selectivity

31 March 2020

1 reference

Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.

31 March 2020

1 reference

Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts

31 March 2020

1 reference

Molecular targeted therapy for neuroendocrine tumors

31 March 2020

1 reference

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

31 March 2020

1 reference

Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration

31 March 2020

1 reference

Incorporation of bone marrow-derived Flk-1-expressing CD34+ cells in the endothelium of tumor vessels in the mouse brain.

31 March 2020

1 reference

Fas/Fas ligand interaction in human colorectal hepatic metastases: A mechanism of hepatocyte destruction to facilitate local tumor invasion

31 March 2020

1 reference

Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia

31 March 2020

1 reference

Distinct angiogenic and non-angiogenic growth patterns of lung metastases from renal cell carcinoma

31 March 2020

1 reference

Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors

31 March 2020

1 reference

Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma

31 March 2020

1 reference

Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us.

31 March 2020

1 reference

Promoting angiogenesis to a fault

31 March 2020

1 reference

Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo.

31 March 2020

1 reference

Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis

31 March 2020

1 reference

Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis

31 March 2020

1 reference

FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer

31 March 2020

1 reference

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer

31 March 2020

1 reference

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

31 March 2020

1 reference

Transplacental carcinogenesis by stilbestrol

31 March 2020

1 reference

Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner

31 March 2020

1 reference

Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation

31 March 2020

1 reference

Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal

31 March 2020

1 reference

SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice

31 March 2020

1 reference

Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST

31 March 2020

1 reference

The anti-angiogenic basis of metronomic chemotherapy

31 March 2020

1 reference

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

31 March 2020

1 reference

Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity.

31 March 2020

1 reference

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

31 March 2020

1 reference

The multifaceted circulating endothelial cell in cancer: towards marker and target identification.

31 March 2020

1 reference

Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth

31 March 2020

1 reference

VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells

31 March 2020

1 reference

SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells

31 March 2020

1 reference

Contribution of bone marrow–derived endothelial cells to human tumor vasculature

31 March 2020

1 reference

Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis

31 March 2020

1 reference

Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth

31 March 2020

1 reference

Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer

31 March 2020

1 reference

Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium.

31 March 2020

1 reference

Nitroglycerin treatment may enhance chemosensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma

31 March 2020

1 reference

Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.

31 March 2020

1 reference

Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer a

31 March 2020

1 reference

Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b

31 March 2020

1 reference

Abnormalities of Basement Membrane on Blood Vessels and Endothelial Sprouts in Tumors

31 March 2020

1 reference

Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors

31 March 2020

1 reference

Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy

31 March 2020

1 reference

Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11.

31 March 2020

1 reference

Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia

31 March 2020

1 reference

Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization.

31 March 2020

1 reference

Functional significance of vascular endothelial growth factor receptors on gastrointestinal cancer cells

31 March 2020

1 reference

Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells

31 March 2020

1 reference

Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer

31 March 2020

1 reference

Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver

31 March 2020

1 reference

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

31 March 2020

1 reference

VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression.

31 March 2020

1 reference

Immunobiology of dendritic cells

31 March 2020

1 reference

Dendritic cells as therapeutic vaccines against cancer

31 March 2020

1 reference

Dendritic cells at the host-pathogen interface

31 March 2020

1 reference

Dendritic Cell Function in Vivo during the Steady State: A Role in Peripheral Tolerance

31 March 2020

1 reference

Chemoattraction of femoral CD34+ progenitor cells by tumor-derived vascular endothelial cell growth factor

31 March 2020

1 reference

Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells

31 March 2020

1 reference

Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses

31 March 2020

1 reference

Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation

31 March 2020

1 reference

Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways.

31 March 2020

1 reference

Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2.

31 March 2020

1 reference

Neuropilin-1 interacts with integrin beta1 and modulates pancreatic cancer cell growth, survival and invasion

31 March 2020

1 reference

Neuropilin structure governs VEGF and semaphorin binding and regulates angiogenesis

31 March 2020

1 reference

Neuropilin-1 and neuropilin-2 act as coreceptors, potentiating proangiogenic activity.

31 March 2020

1 reference

The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRC2403

1 reference

Dimensions Publication ID

4 August 2017

0 references

1 reference